Noninvasive strategies for metabolic dysfunction-associated steatotic liver disease assessment and referral in Japan

Table 5 Cutoffs for the enhanced liver fibrosis test

Ref.	Study design	Stage 1	Stage 2	Stage 3	Stage 4
Nobili et al[29], 2009	Cross-sectional	9.28	10.18	10.51	-
Inadomi et al[30], 2020	Cross-sectional	-	9.86	10.38	-
Seko et al[31], 2023	Cross-sectional	9.1	10.11	11.1	11.54
Sanyal et al[35], 2023	Cross-sectional	-	8.8/10.01	9.2/10.41	9.7/10.91
Hinkson et al[32], 2023	Meta-analysis	-	9.5	9.6	-
Vali et al[33], 2020	Meta-analysis	-	9.37	9.43	-
Sanyal et al[34], 2019	Longitudinal	-	-	9.82	11.32

¹Cutoff with sensitivity ≥ 90% and specificity ≥ 90%.

²Cutoff for the prediction of clinical event.